trending Market Intelligence /marketintelligence/en/news-insights/trending/osW9qfHNSzKxuIu2U52vkQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

3M agrees to sell drug delivery business to Altaris Capital Partners for $650M

Street Talk Episode 56 - Latest bank MOE shows even the strong need scale to thrive

South State CenterState MOE Shows Even The Strong Need Scale To Thrive

Talking Bank Stocks, Playing The M&A Trade With Longtime Investor

Report: Kashkari Says Fed In Holding Pattern But Rate Cut Still Possible

3M agrees to sell drug delivery business to Altaris Capital Partners for $650M

Minnesota-based 3M Co. agreed to divest substantially all of its drug delivery business to an affiliate of Altaris Capital Partners LLC for approximately $650 million, inclusive of cash.

3M expects to earn a net gain of 45 cents to 50 cents per share from the sale.

Following completion, pegged for the first half of 2020, 3M's ownership interest in the drug delivery business will be recorded using the equity method of accounting.

Morgan Stanley & Co. LLC served as financial adviser, and Cleary Gottlieb Steen & Hamilton LLP was legal counsel to 3M on the transaction.